Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.

M, Okada; J, Imagawa; H, Tanaka; H, Nakamae; M, Hino; K, Murai; Y, Ishida; T, Kumagai; S, Sato; K, Ohashi; H, Sakamaki; H, Wakita; N, Uoshima; Y, Nakagawa; Y, Minami; M, Ogasawara; T, Takeoka; H, Akasaka; T, Utsumi; N, Uike; T, Sato; S, Ando; K, Usuki; S, Mizuta; S, Hashino; T, Nomura; M, Shikami; H, Fukutani; Y, Ohe; H, Kosugi; H, Shibayama; Y, Maeda; T, Fukushima; H, Yamazaki; K, Tsubaki; T, Kukita; Y, Adachi; T, Nataduka; H, Sakoda; H, Yokoyama; T, Okamoto; Y, Shirasugi; Y, Onishi; M, Nohgawa; S, Yoshihara; S, Morita; J, Sakamoto; S, Kimura

doi:10.1016/j.clml.2018.03.004

Public

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.

Shared by NobleBlocks on Mar 15, 2018 • 12:00 AM UTC

Authors:

Okada M

Imagawa J

Tanaka H

Abstract

<h4>Introduction</h4>We previously reported an interim analysis of the DADI (dasatinib discontinuation) trial. The results showed that 48% of patients with chronic myeloid leukemia in the chronic phase who maintained a deep molecular response (DMR) for ≥ 1 year could discontinue second- or subsequen...

Subject

CML

Natural killer cell

Treatment-free Remission

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!